Form 4: Column Group III Increases Stake in Surrozen

The Column Group III GP, LP and affiliated entities reported acquiring additional common stock in Surrozen, Inc. through pre-planned transactions.

Summary

• The Column Group III GP, LP, a 10% owner and director of Surrozen, Inc. (SRZN), reported multiple acquisitions of common stock.
• On January 13, 2026, The Column Group III, LP acquired 5,861 shares at $19.8041 per share, increasing its indirect beneficial ownership to 882,418 shares.
• On the same date, The Column Group III-A, LP acquired 6,609 shares at $19.8041 per share, increasing its indirect beneficial ownership to 996,502 shares.
• On January 14, 2026, The Column Group III, LP acquired an additional 2,596 shares at $19.9883 per share, bringing its total indirect beneficial ownership to 885,014 shares.
• Also on January 14, 2026, The Column Group III-A, LP acquired 2,927 shares at $19.9883 per share, resulting in a total indirect beneficial ownership of 999,429 shares.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan.
• The Column Group Opportunity III, LP also indirectly beneficially owns 344,827 shares of common stock.
• The managing partners of The Column Group III GP, LP, Peter Svennilson and Tim Kutzkey (a board member of Surrozen), may be deemed to share voting and investment power over these securities.

Sentiment

Score: 7

Explanation: The insider buying by a significant institutional investor and director group is a positive signal, indicating confidence in the company's prospects. The Rule 10b5-1 plan somewhat tempers the immediate discretionary signal but still represents a commitment to increasing ownership.

Positives

• Significant insider buying by a 10% owner and director group suggests confidence in Surrozen's future prospects.
• The acquisitions were made at prices ranging from $19.8041 to $19.9883, indicating a belief in the stock's value at these levels.
• The total number of shares acquired across the two days is 17,993, representing a continued investment.

Negatives

• The transactions were executed under a Rule 10b5-1 plan, which means they were pre-scheduled and do not necessarily reflect a new, immediate discretionary decision to buy based on recent non-public information.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, beyond the implication of continued investment by a significant shareholder.

Industry Context

Insider buying by a major institutional investor and director group in a biotechnology or pharmaceutical company like Surrozen Inc. can signal confidence in the company's pipeline, clinical trial progress, or strategic direction, especially in a sector often characterized by high risk and high reward.

Related Party Transactions

• The filing details acquisitions of common stock by The Column Group III GP, LP and its affiliated entities, which are 10% owners and include a director of Surrozen, Inc. These transactions are considered related party dealings due to the reporting persons' significant relationship with the issuer.

Stakeholder Impact

• Shareholders: The insider buying could be interpreted as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: The continued investment by a significant shareholder and director group aligns interests and may reinforce strategic decisions.

Key Dates

Recommendation

The consistent buying activity by a significant institutional investor and director group, even under a Rule 10b5-1 plan, signals strong conviction in Surrozen's long-term value. Such insider purchases often precede positive developments or reflect a belief that the stock is undervalued. While not a guarantee, it provides a strong bullish indicator for seasoned investors.

Keywords

Surrozen Inc, SRZN, SEC Form 4, insider buying, beneficial ownership, The Column Group, stock acquisition, Rule 10b5-1, director ownership, 10% owner